MXPA05013392A - Composiciones farmaceuticas de atorvastatina. - Google Patents
Composiciones farmaceuticas de atorvastatina.Info
- Publication number
- MXPA05013392A MXPA05013392A MXPA05013392A MXPA05013392A MXPA05013392A MX PA05013392 A MXPA05013392 A MX PA05013392A MX PA05013392 A MXPA05013392 A MX PA05013392A MX PA05013392 A MXPA05013392 A MX PA05013392A MX PA05013392 A MXPA05013392 A MX PA05013392A
- Authority
- MX
- Mexico
- Prior art keywords
- dosage form
- unit dosage
- atorvastatin
- per
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Abstract
Una forma farmaceutica unitaria que comprende atorvastatina o una de sus sales farmaceuticamente aceptable, prepara sin etapa de granulacion, en la que la potencia medida de la atorvastatina de dicha forma farmaceutica muestra una desviacion tipica relativa (RSD) para la potencia de la atorvastatina por forma farmaceutica unitaria, de no mas del 7.8% aproximadamente, cuando dicha forma farmaceutica unitaria se prepara a una velocidad que es mayor de 10,000 formas farmaceuticas unitarias por hora, por una sola forma farmaceutica unitaria, por maquina, asi como tambien la forma farmaceutica unitaria en combinacion con al menos un farmaco activo, metodos de preparacion de la forma farmaceutica unitaria, kits para contener tales composiciones y un metodo de tratamiento de la hipercolesterolemia y/o la hiperlipidemia, la osteoporosis, la hiperplasia prostatica benigna (BPH) y la enfermedad de Alzheimer, cuando un cantidad terapeuticamente eficaz de la forma farmaceutica unitaria.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47791803P | 2003-06-12 | 2003-06-12 | |
PCT/IB2004/001845 WO2004110409A1 (en) | 2003-06-12 | 2004-06-01 | Pharmaceutical compositions comprising atorvastatin manufactured without granulation |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA05013392A true MXPA05013392A (es) | 2006-03-09 |
Family
ID=33551781
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA05013392A MXPA05013392A (es) | 2003-06-12 | 2004-06-01 | Composiciones farmaceuticas de atorvastatina. |
Country Status (23)
Country | Link |
---|---|
US (2) | US20050271717A1 (es) |
EP (2) | EP1977738A1 (es) |
JP (1) | JP2006527256A (es) |
KR (1) | KR20060028768A (es) |
CN (1) | CN100446757C (es) |
AR (1) | AR044775A1 (es) |
AT (1) | ATE399537T1 (es) |
AU (1) | AU2004246866A1 (es) |
BR (1) | BRPI0411079A (es) |
CA (1) | CA2465621A1 (es) |
CO (1) | CO5640072A2 (es) |
DE (1) | DE602004014765D1 (es) |
DK (1) | DK1635791T3 (es) |
ES (1) | ES2305775T3 (es) |
MX (1) | MXPA05013392A (es) |
NO (1) | NO20055185L (es) |
PL (1) | PL1635791T3 (es) |
PT (1) | PT1635791E (es) |
RU (1) | RU2314804C2 (es) |
SI (1) | SI1635791T1 (es) |
TW (1) | TW200509905A (es) |
WO (1) | WO2004110409A1 (es) |
ZA (1) | ZA200509906B (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
WO2007047863A2 (en) * | 2005-10-19 | 2007-04-26 | Teva Pharmaceutical Industries, Ltd. | Crystals of laquinimod sodium, and process for the manufacture thereof |
EP1810667A1 (en) * | 2006-01-20 | 2007-07-25 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition comprising amorphous atorvastatin |
DK2035001T3 (da) * | 2006-06-12 | 2012-02-27 | Teva Pharma | Stabile laquinimod-tilberedninger |
US20080249141A1 (en) * | 2007-04-06 | 2008-10-09 | Palepu Nageswara R | Co-therapy with and combinations of statins and 1,4-dihydropyridine-3,5-dicarboxydiesters |
DE102007052071A1 (de) * | 2007-10-30 | 2009-05-07 | Stada Arzneimittel Ag | Stabilisiertes Atorvastatin |
PT2682120T (pt) * | 2007-12-20 | 2016-11-07 | Teva Pharma | Preparações de laquinimod estáveis |
WO2009116061A2 (en) * | 2008-01-10 | 2009-09-24 | Alkem Laboratories Ltd. | Stable oral pharmaceutical composition comprising atorvastatin |
GB0800788D0 (en) * | 2008-01-16 | 2008-02-27 | Glaxo Group Ltd | Niovel formulation |
CA2637977A1 (en) * | 2008-07-15 | 2010-01-15 | Pharmascience Inc. | Dosage form containing a statin |
CN104311486A (zh) * | 2008-09-03 | 2015-01-28 | 泰华制药工业有限公司 | 2-羰基-1,2-二氢喹啉免疫功能调节剂 |
PL2458992T3 (pl) * | 2009-07-30 | 2016-07-29 | Teva Pharma | Leczenie choroby Leśniowskiego-Crohna z użyciem lakwinimodu |
ME02495B (me) * | 2009-08-10 | 2017-02-20 | Teva Pharma | Tretman poremećaja koji su u vezi sa bdnf primenom lakvinimoda |
WO2011028309A1 (en) | 2009-09-04 | 2011-03-10 | University Of Toledo | PROCESSES FOR PRODUCING OPTICALLY PURE β-LACTONES FROM ALDEHYDES AND COMPOSITIONS PRODUCED THEREBY |
KR101248804B1 (ko) * | 2010-05-14 | 2013-03-29 | 한미사이언스 주식회사 | HMG-CoA 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제 |
US8889627B2 (en) | 2011-10-12 | 2014-11-18 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
AR089862A1 (es) | 2012-02-03 | 2014-09-24 | Teva Pharma | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA |
TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
MX2015005632A (es) | 2012-11-07 | 2016-02-05 | Teva Pharma | Sales de amina de laquinimod. |
JP2016514162A (ja) | 2013-03-14 | 2016-05-19 | テバ ファーマシューティカル インダストリーズ リミティド | ラキニモドナトリウムの結晶およびその製造のための改善された方法 |
CN111698992A (zh) * | 2017-08-18 | 2020-09-22 | 艾伯维公司 | 用于治疗子宫内膜异位症、子宫肌瘤、多囊卵巢综合症或子宫腺肌症的药物配制物 |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
US5124482A (en) * | 1988-02-22 | 1992-06-23 | Warner-Lambert Company | Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis |
US5245047A (en) * | 1988-02-22 | 1993-09-14 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5097045A (en) * | 1989-02-01 | 1992-03-17 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5216174A (en) * | 1988-02-22 | 1993-06-01 | Warner-Lambert Co. | Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5149837A (en) * | 1988-02-22 | 1992-09-22 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5003080A (en) * | 1988-02-22 | 1991-03-26 | Warner-Lambert Company | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis |
FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5248793A (en) * | 1990-10-17 | 1993-09-28 | Warner-Lambert Company | Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
US5103024A (en) * | 1990-10-17 | 1992-04-07 | Warner-Lambert Company | Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
US5155251A (en) * | 1991-10-11 | 1992-10-13 | Warner-Lambert Company | Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate |
EP0680320B1 (en) * | 1993-01-19 | 1999-04-14 | Warner-Lambert Company | Stable oral ci-981 formulation and process of preparing same |
US5298627A (en) * | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
HRP960312B1 (en) * | 1995-07-17 | 2001-10-31 | Warner Lambert Co | NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1) |
BR9609872A (pt) * | 1995-07-17 | 1999-03-23 | Warner Lambert Co | Hemi sal de cálcio de ácido (R-(R*R*)]-2-(4-fluorfenil-)-beta delta-diidróxi-5-(1-metiletil)-3-fenil-4- [(fenilamino) carbonil]-1H- pirrol-1heptanóico (atorvasta-tina)c ristalino |
HRP960313B1 (en) * | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
US6087511A (en) * | 1996-07-16 | 2000-07-11 | Warner-Lambert Company | Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1) |
DK0915866T3 (da) * | 1996-07-29 | 2002-06-10 | Warner Lambert Co | Forbedret fremgangsmåde til syntese af beskyttende estere af (S)-3,4-dihydroxysmørsyre |
GT199800127A (es) * | 1997-08-29 | 2000-02-01 | Combinaciones terapeuticas. | |
HUP0100252A3 (en) * | 1997-12-19 | 2002-12-28 | Warner Lambert Exp Ltd Dun Lao | Process for the synthesis of 1,3-diols |
US6287594B1 (en) * | 1998-01-20 | 2001-09-11 | Edward S. Wilson | Oral liquid compositions |
SI20109A (sl) * | 1998-12-16 | 2000-06-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Stabilna farmacevtska formulacija |
IN191236B (es) | 1999-05-25 | 2003-10-11 | Ranbaxy Lab Ltd | |
US6395300B1 (en) * | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
HU226640B1 (en) | 1999-10-18 | 2009-05-28 | Egis Gyogyszergyar Nyilvanosan | Process for producing amorphous atorvastatin calcium salt |
EP1235799B1 (en) | 1999-11-17 | 2005-02-09 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
SI20425A (sl) | 1999-12-10 | 2001-06-30 | LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. | Priprava amorfnega atorvastatina |
DK1274401T4 (da) | 2000-04-10 | 2014-09-08 | Teva Pharma | Stabile farmaceutiske sammensætninger indeholdende 7-substituerede-3,5-dihydroxyheptansyrer eller 7-substituerede-3,5-dihydroxyheptensyrer |
CN1535139A (zh) | 2000-11-03 | 2004-10-06 | ������ҩ��ҵ����˾ | 阿伐他丁半钙形式ⅶ |
CA2427255A1 (en) | 2000-11-16 | 2002-06-06 | Teva Pharmaceutical Industries Ltd. | Hydrolysis of [r(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta. -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide |
IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
PL365312A1 (en) | 2000-12-27 | 2004-12-27 | Teva Pharmaceutical Industries Ltd | Crystalline forms of atorvastatin |
US6476235B2 (en) * | 2001-01-09 | 2002-11-05 | Warner-Lambert Company | Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide |
WO2002057228A1 (en) | 2001-01-17 | 2002-07-25 | Biocon India Limited | Atorvastatin calcium |
WO2002057229A1 (en) | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
SI20814A (sl) | 2001-01-23 | 2002-08-31 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Priprava amorfnega atorvastatina |
SI20848A (sl) * | 2001-03-14 | 2002-10-31 | Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. | Farmacevtska formulacija, ki vsebuje atorvastatin kalcij |
EP1243524A3 (en) | 2001-03-16 | 2004-04-07 | Pfizer Products Inc. | Pharmaceutical kit for oxygen-sensitive drugs |
EP1241110A1 (en) | 2001-03-16 | 2002-09-18 | Pfizer Products Inc. | Dispensing unit for oxygen-sensitive drugs |
IN190564B (es) | 2001-04-11 | 2003-08-09 | Cadila Heathcare Ltd | |
GEP20053546B (en) * | 2001-06-29 | 2005-06-10 | Warner Lambert Co | Crystalline Forms of 'R-(R*,R*)!-2-(4- Fluorophenyl)-Beta, Delta-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-'Phenylamino) Carbonyl!-1H-Pyrrole-1-Heptanoic Acid Calcium Salt (2:1) (Atorvastatin) |
CN100471836C (zh) | 2001-07-30 | 2009-03-25 | 雷迪实验室有限公司 | 托伐他汀钙晶型vi和vii |
EP1414496B1 (en) * | 2001-08-07 | 2010-10-20 | Galephar M/F | Pharmaceutical composition containing a combinaition of ppar-alpha, pravastatin and polyglycolized glyceride |
UA77990C2 (en) | 2001-12-12 | 2007-02-15 | Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid | |
AR038839A1 (es) * | 2002-02-14 | 2005-01-26 | Ranbaxy Lab Ltd | Formulacion de atorvastatina estabilizada con aditamentos de metales alcalinos. metodo para su elaboracion |
CA2475864A1 (en) | 2002-02-15 | 2003-08-28 | Teva Pharmaceutical Industries Ltd. | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix |
PA8576201A1 (es) * | 2002-07-10 | 2004-05-26 | Pfizer Prod Inc | Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco |
WO2004022053A1 (en) | 2002-09-03 | 2004-03-18 | Morepen Laboratories Limited | Atorvastatin calcium form vi or hydrates thereof |
US7655692B2 (en) | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
-
2004
- 2004-04-20 US US10/828,419 patent/US20050271717A1/en not_active Abandoned
- 2004-04-29 CA CA002465621A patent/CA2465621A1/en not_active Abandoned
- 2004-06-01 EP EP08153178A patent/EP1977738A1/en not_active Withdrawn
- 2004-06-01 DK DK04735619T patent/DK1635791T3/da active
- 2004-06-01 DE DE602004014765T patent/DE602004014765D1/de not_active Revoked
- 2004-06-01 JP JP2006516504A patent/JP2006527256A/ja active Pending
- 2004-06-01 EP EP04735619A patent/EP1635791B1/en not_active Revoked
- 2004-06-01 WO PCT/IB2004/001845 patent/WO2004110409A1/en active IP Right Grant
- 2004-06-01 KR KR1020057023838A patent/KR20060028768A/ko active IP Right Grant
- 2004-06-01 MX MXPA05013392A patent/MXPA05013392A/es unknown
- 2004-06-01 ES ES04735619T patent/ES2305775T3/es active Active
- 2004-06-01 CN CNB2004800143122A patent/CN100446757C/zh not_active Expired - Fee Related
- 2004-06-01 SI SI200430802T patent/SI1635791T1/sl unknown
- 2004-06-01 RU RU2005138496/15A patent/RU2314804C2/ru not_active IP Right Cessation
- 2004-06-01 PL PL04735619T patent/PL1635791T3/pl unknown
- 2004-06-01 BR BRPI0411079-0A patent/BRPI0411079A/pt not_active IP Right Cessation
- 2004-06-01 AU AU2004246866A patent/AU2004246866A1/en not_active Abandoned
- 2004-06-01 PT PT04735619T patent/PT1635791E/pt unknown
- 2004-06-01 AT AT04735619T patent/ATE399537T1/de not_active IP Right Cessation
- 2004-06-10 AR ARP040102010A patent/AR044775A1/es unknown
- 2004-06-11 TW TW093116996A patent/TW200509905A/zh unknown
-
2005
- 2005-11-04 NO NO20055185A patent/NO20055185L/no not_active Application Discontinuation
- 2005-12-06 ZA ZA200509906A patent/ZA200509906B/en unknown
- 2005-12-12 CO CO05125195A patent/CO5640072A2/es not_active Application Discontinuation
-
2009
- 2009-05-08 US US12/424,972 patent/US20090226510A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1977738A1 (en) | 2008-10-08 |
US20090226510A1 (en) | 2009-09-10 |
BRPI0411079A (pt) | 2006-07-25 |
SI1635791T1 (sl) | 2008-10-31 |
PT1635791E (pt) | 2008-09-10 |
PL1635791T3 (pl) | 2008-11-28 |
RU2005138496A (ru) | 2006-04-27 |
NO20055185L (no) | 2006-03-09 |
CO5640072A2 (es) | 2006-05-31 |
TW200509905A (en) | 2005-03-16 |
WO2004110409A1 (en) | 2004-12-23 |
DK1635791T3 (da) | 2008-08-25 |
CA2465621A1 (en) | 2004-12-12 |
DE602004014765D1 (de) | 2008-08-14 |
JP2006527256A (ja) | 2006-11-30 |
US20050271717A1 (en) | 2005-12-08 |
EP1635791A1 (en) | 2006-03-22 |
ATE399537T1 (de) | 2008-07-15 |
NO20055185D0 (no) | 2005-11-04 |
RU2314804C2 (ru) | 2008-01-20 |
KR20060028768A (ko) | 2006-04-03 |
AU2004246866A1 (en) | 2004-12-23 |
AR044775A1 (es) | 2005-10-05 |
ES2305775T3 (es) | 2008-11-01 |
CN1794978A (zh) | 2006-06-28 |
CN100446757C (zh) | 2008-12-31 |
ZA200509906B (en) | 2007-01-31 |
EP1635791B1 (en) | 2008-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA05013392A (es) | Composiciones farmaceuticas de atorvastatina. | |
GEP20043314B (en) | Pharmaceutical Composition Comprising Entacapone, Levodopa, and Carbidopa | |
AP1818A (en) | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain | |
NO20060149L (no) | Farmasoytiske forbindelser av atorvastatin | |
ATE235895T1 (de) | Arzneistoff-abgabesystem enthaltend eine festgepackte, feste arzneistoffbasis | |
AU7031500A (en) | Therapeutic quinazoline compounds | |
ATE423556T1 (de) | Capsaicin-enthaltende missbrauchsichere pharmazeutische zusammensetzungen | |
UA88270C2 (ru) | Фармацевтический препарат и его применение для профилактики удара, диабета | |
AU2002359164A1 (en) | Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 | |
GEP20053595B (en) | Cyclopentanoindoles, Compositions Containing Such Compounds and Methods of Treatment | |
WO2002042462A3 (en) | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease | |
GEP20053673B (en) | Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents | |
SE9901573D0 (sv) | New compounds | |
WO2002088100A3 (de) | Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel | |
PL370529A1 (en) | Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug | |
AU2002359162A1 (en) | Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3 | |
SE0102440D0 (sv) | New compound | |
IL150817A0 (en) | Pyrrole-type compounds, compositions, and methods for treating cancer or viral diseases | |
MXPA05013281A (es) | Composiciones farmaceuticas de atorvastatina. | |
SE9901572D0 (sv) | New compounds | |
CA2432177A1 (en) | Drug for prevention and/or therapy of endometriosis | |
AU2173101A (en) | Use of carboxy compounds such as 2(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride as anti-inflammatory agents | |
GEP20043377B (en) | Pharmaceutical Complex | |
MY133438A (en) | Morpholinobenzamide salts | |
AU2003304547A1 (en) | Fiber rich fraction of trigonella foenum-graecum and its use as a pharmaceutcal excipient |